Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
Mar 5, 2024 | Appropriateness Solutions, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Value
At January’s Benefits Advisory Conference, MedBen President & CEO Kurt Harden observed that when the Food and Drug Administration (FDA) evaluates a new drug to be approved for sale, it has to be safe and effective, but not necessarily superior to...
Feb 6, 2024 | Claims, Cost Savings, Drug costs, Gene therapy, Genetic testing, MedBen Rx, MedBen University, News, Pharmacogenomics, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs
MedBen recently had the honor to welcome some of the most respected names in the benefits management industry. At the invitation-only 2024 Benefits Advisory Conference on January 26, attending brokers learned about health plan innovations that will help self-funded...
Jan 22, 2024 | Access solutions, Benefits preservation, MedBen Rx, Pharmacies, Prescription drugs, Specialty Drugs
A recent Segal Health Plan Cost Trend Survey projects 2024 cost trend for prescription drugs to approach 10%… but specialty drug trend alone may reach 15% this year, as increased use of expensive drugs continues to drive costs up. (We’ve actually seen...
Jan 5, 2024 | Access solutions, Acquisition Cost Index (ACI), Appropriateness Solutions, Benefits preservation, Comparative Effectiveness, Drug costs, MedBen Rx, Pricing solutions, Specialty Drugs
Pfizer, Sanofi, Takeda Pharmaceutical, and other drugmakers will raise the prices of more than 500 drugs in early January, according to an analysis by health care researchers 3 Axis Advisors. Inflation and rising manufacturing costs will contribute to the price...
